Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jun 29;103(3):391–400. doi: 10.1038/sj.bjc.6605764

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2010 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

(A) Plots of peak height against m/z for the identification of ApoA-II isoforms using SELDI RS100 profiles. (a) ApoA-II purified human plasma ApoA-II (Sigma-Aldrich) IgG, (b) serum without IgG, (c) purified human ApoA-II on ApoA-II antibody-enriched chip indicating a number if peaks ∼8603 indicating monomer and 17 132 indicating dimer, (d) purified ApoA-II treated with 20 μM DTT for 3 h on antibody-enriched chip, (e) serum on ApoA-II antibody-enriched chip and (f) purified ApoA-II treated with 20 μM DTT for 3 h on antibody-enriched chip. (B) Western blotting analysis of the effect of 0 to 4 h of 20 μM DTT reduction on a serum sample and on purified human plasma ApoA-II. (C) Western blot of the expression of ApoC-I and ∼17 kDa ApoA-II in five pancreatic cancer samples (PC), five disease control samples (DC) and five human volunteer samples (HV). (D) Plot of mean and s.d. band intensity (% of HV) as semiquantified by Pro-Gel scanning (Gel-Pro Analyzer Properties) for PC samples (n=15), DC samples (n=15) and HV samples (n=15).